{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:31:07Z","timestamp":1790965867949,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cardiotoxicity is the most significant adverse event associated with trastuzumab (T), the main component of HER2-positive breast cancer (BC) treatment. Less is known about the cardiotoxicity of dual HER2 blockade with T plus lapatinib (L), although this regimen is used in the metastatic setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a sub-analysis of the ALTTO trial comparing adjuvant treatment options for patients with early HER2-positive BC. Patients randomised to either T or concomitant T\u2009+\u2009L were eligible. Cardiac events (CEs) rates were compared according to treatment arm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>With 6.9 years of median follow-up (FU) and 4190 patients, CE were observed in 363 (8.6%): 166 (7.9%) of patient in T\u2009+\u2009L arm vs. 197 (9.3%) in T arm (OR\u2009=\u20090.85 [95% CI, 0.68\u20131.05]). During anti-HER2 treatment 270 CE (6.4%) occurred while 93 (2.2%) were during FU (median time to onset\u2009=\u20096.6 months [IQR\u2009=\u20093.4\u201311.7]). While 265 CEs were asymptomatic (73%), 94 were symptomatic (26%) and four were cardiac deaths (1%). Recovery was observed in 301 cases (83.8%). Identified cardiac risk factors were: baseline LVEF\u2009&lt;\u200955% (vs\u2009&gt;\u200964%, OR 3.1 [95% CI 1.54\u20136.25]), diabetes mellitus (OR 1.85 [95% CI 1.25\u20132.75]), BMI\u2009&gt;\u200930\u2009kg\/m<jats:sup>2<\/jats:sup> (vs\u2009&lt;\u200925\u2009mg\/kg<jats:sup>2<\/jats:sup>, OR 2.21 [95% CI 1.40\u20133.49]), cumulative dose of doxorubicin \u2265240\u2009mg\/m<jats:sup>2<\/jats:sup> (OR 1.36 [95% CI 1.01\u20131.82]) and of epirubicin\u2265 480\u2009mg\/m<jats:sup>2<\/jats:sup> (OR 2.33 [95% CI 1.55\u20133.51]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Dual HER2 blockade with T\u2009+\u2009L is a safe regimen from a cardiac perspective, but cardiac-focused history for proper patient selection is crucial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: NCT00490139 (registration date: 22\/06\/2007); EudraCT Number: 2006\u2013000562\u201336 (registration date: 04\/05\/2007); Sponsor Protocol Number: BIG2\u201306 \/EGF106708\/N063D.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-0786-x","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:02:13Z","timestamp":1584316933000},"page":"1453-1460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab Treatment Optimization Trial"],"prefix":"10.1038","volume":"122","author":[{"given":"Daniel","family":"Eiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam F.","family":"Pond\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Agbor-Tarh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Moreno-Aspitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentine S.","family":"Hilbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saranya","family":"Chumsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"L\u00e1ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Rodeheffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Suter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"786_CR1","doi-asserted-by":"publisher","unstructured":"Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V. et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD006243.pub2 (2012).","DOI":"10.1002\/14651858.CD006243.pub2"},{"key":"786_CR2","doi-asserted-by":"publisher","first-page":"e000073","DOI":"10.1136\/esmoopen-2016-000073","volume":"1","author":"NF Pond\u00e9","year":"2016","unstructured":"Pond\u00e9, N. F., Lambertini, M. & de Azambuja, E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 1, e000073 (2016).","journal-title":"ESMO Open"},{"key":"786_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 377, 122\u2013131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"786_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M. et al. Pertuzumab, Trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724\u2013734 (2015).","journal-title":"N. Engl. J. Med."},{"key":"786_CR5","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","volume":"34","author":"M Piccart-Gebhart","year":"2016","unstructured":"Piccart-Gebhart, M., Holmes, E., Baselga, J., de Azambuja, E., Dueck, A. C., Viale, G. et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial. J. Clin. Oncol. 34, 1034\u20131042 (2016).","journal-title":"J. Clin. Oncol."},{"key":"786_CR6","doi-asserted-by":"publisher","unstructured":"Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T. et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz189 (2019).","DOI":"10.1093\/annonc\/mdz189"},{"key":"786_CR7","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., Andr\u00e9, F. et al. 4th ESO\u2013ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020. Ann. Oncol. 29, 1634\u20131657 (2018).","journal-title":"Ann. Oncol."},{"key":"786_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/0008-5472.CAN-05-2506","volume":"66","author":"Y Zhou","year":"2006","unstructured":"Zhou, Y., Li, S., Hu, Y. P., Wang, J., Hauser, J., Conway, A. N. et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 66, 404\u2013411 (2006).","journal-title":"Cancer Res."},{"key":"786_CR9","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/JCO.2018.79.2697","volume":"36","author":"SH Giordano","year":"2018","unstructured":"Giordano, S. H., Temin, S., Chandarlapaty, S., Crews, J. R., Esteva, F. J., Kirshner, J. J. et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 36, 2736\u20132740, https:\/\/doi.org\/10.1200\/JCO.2018.79.2697 (2018).","journal-title":"J. Clin. Oncol."},{"key":"786_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459\u2013465 (2002).","journal-title":"Nat. Med."},{"key":"786_CR11","doi-asserted-by":"publisher","first-page":"8880","DOI":"10.1073\/pnas.122249299","volume":"99","author":"C \u00d6zcelik","year":"2002","unstructured":"\u00d6zcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., H\u00fcbner, N. et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl Acad. Sci. USA 99, 8880\u20138885 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"786_CR12","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer, M. S. & Lippman, S. M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. 23, 2900\u20132902 (2005).","journal-title":"J. Clin. Oncol."},{"key":"786_CR13","doi-asserted-by":"publisher","first-page":"djv301","DOI":"10.1093\/jnci\/djv301","volume":"108","author":"HA Goldhar","year":"2016","unstructured":"Goldhar, H. A., Yan, A. T., Ko, D. T., Earle, C. C., Tomlinson, G. A., Trudeau, M. E. et al. The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study. J. Natl Cancer Inst. 108, djv301 (2016).","journal-title":"J. Natl Cancer Inst."},{"key":"786_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.yjmcc.2006.08.002","volume":"41","author":"F Timolati","year":"2006","unstructured":"Timolati, F., Ott, D., Pentassuglia, L., Giraud, M. N., Perriard, J. C., Suter, T. M. et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J. Mol. Cell Cardiol. 41, 845\u2013854 (2006).","journal-title":"J. Mol. Cell Cardiol."},{"key":"786_CR15","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","volume":"105","author":"DB Sawyer","year":"2002","unstructured":"Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M. & Suter, T. M. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105, 1551\u20131554 (2002).","journal-title":"Circulation"},{"key":"786_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J., Cort\u00e9s, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109\u2013119 (2012).","journal-title":"N. Engl. J. Med."},{"key":"786_CR17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1634\/theoncologist.2016-0406","volume":"22","author":"AF Yu","year":"2017","unstructured":"Yu, A. F., Singh, J. C., Wang, R., Liu, J. E., Eaton, A., Oeffinger, K. C. et al. Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer. Oncologist 22, 642\u2013647 (2017).","journal-title":"Oncologist"},{"key":"786_CR18","doi-asserted-by":"publisher","unstructured":"Ponde, N. F., Ameye, L., Lambertini, M., Paesmans, M., De Azambuja, E. An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/jco.2018.36.15_suppl.10068 (2018).","DOI":"10.1200\/jco.2018.36.15_suppl.10068"},{"key":"786_CR19","doi-asserted-by":"publisher","first-page":"10607","DOI":"10.1073\/pnas.0701286104","volume":"104","author":"NL Spector","year":"2007","unstructured":"Spector, N. L., Yarden, Y., Smith, B., Lyass, L., Trusk, P., Pry, K. et al. Activation of AMP-activated protein kinase by human EGF receptor 2\/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc. Natl Acad. Sci. USA 104, 10607\u201310612 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"786_CR20","doi-asserted-by":"publisher","unstructured":"Florido, R., Smith, K. L., Cuomo, K. K., Russell, S. D. Cardiotoxicity from human epidermal growth factor receptor\u20102 (HER2) targeted therapies. J. Am. Heart. Assoc. https:\/\/doi.org\/10.1161\/JAHA.117.006915 (2017).","DOI":"10.1161\/JAHA.117.006915"},{"key":"786_CR21","doi-asserted-by":"publisher","unstructured":"Yang, S. N., Sun, S. S., Zhang, G., Chou, K. T., Lo, S. W., Chiou, Y. R. et al. Left ventricular ejection fraction estimation using mutual information on technetium-99m multiple-gated SPECT scans. Biomed. Eng. Online https:\/\/doi.org\/10.1186\/s12938-015-0117-2 (2015).","DOI":"10.1186\/s12938-015-0117-2"},{"key":"786_CR22","doi-asserted-by":"crossref","unstructured":"Bellenger, N. G., Burgess, M. I., Ray, S. G., Lahiri, A., Coats, A. J. S., Cleland, J. G. F. et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable? Eur. Heart J. 21, 1387\u20131396 (2000).","DOI":"10.1053\/euhj.2000.2011"},{"key":"786_CR23","doi-asserted-by":"publisher","unstructured":"de Azambuja, E., Ponde, N., Procter, M., Rastogi P., Cecchini R. S., Lambertini M. et al. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res. Treat. https:\/\/doi.org\/10.1007\/s10549-019-05453-z (2019).","DOI":"10.1007\/s10549-019-05453-z"},{"key":"786_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1634\/theoncologist.2015-0230","volume":"21","author":"SC Seferina","year":"2016","unstructured":"Seferina, S. C., de Boer, M., Derksen, M. W., van den Berkmortel, F., van Kampen, R. J. W., van de Wouw, A. J. et al. Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily dutch practice: a study of the Southeast Netherlands Breast Cancer Consortium. Oncologist 21, 555\u2013562 (2016).","journal-title":"Oncologist"},{"key":"786_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-008-0260-6","volume":"117","author":"D Wadhwa","year":"2009","unstructured":"Wadhwa, D., Fallah-Rad, N., Grenier, D., Krahn, M., Fang, T., Ahmadie, R. et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res. Treat. 117, 357\u2013364 (2009).","journal-title":"Breast Cancer Res. Treat."},{"key":"786_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","volume":"18","author":"L Tarantini","year":"2012","unstructured":"Tarantini, L., Cioffi, G., Gori, S., Tuccia, F., Boccardi, L., Bovelli, D. et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J. Card. Fail 18, 113\u2013119 (2012).","journal-title":"J. Card. Fail"},{"key":"786_CR27","doi-asserted-by":"publisher","unstructured":"Lidbrink E., Erfan J., Chmielowska E., Otremba B., Bouhlel A., Lauer S. et al. 175POHERA: A real world study of cardiac events in\u2009>\u20093700 patients with her2-positive early breast cancer treated with trastuzumab: final analysis. Ann. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx362.025 (2017).","DOI":"10.1093\/annonc\/mdx362.025"},{"key":"786_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot, X., Romieu, G., Debled, M., Pierga, J.-Y., Kerbrat, P., Bachelot, T. et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 14, 741\u2013748 (2013).","journal-title":"Lancet Oncol."},{"key":"786_CR29","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","volume":"26","author":"D Mavroudis","year":"2015","unstructured":"Mavroudis, D., Saloustros, E., Malamos, N., Kakolyris, S., Boukovinas, I., Papakotoulas, P. et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann. Oncol. 26, 1333\u20131340 (2015).","journal-title":"Ann. Oncol."},{"key":"786_CR30","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","volume":"29","author":"P Conte","year":"2018","unstructured":"Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O. et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study\u2021. Ann. Oncol. 29, 2328\u20132333 (2018).","journal-title":"Ann. Oncol."},{"key":"786_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","volume":"4","author":"H Joensuu","year":"2018","unstructured":"Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M. et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2\u2013positive breast cancer. JAMA Oncol. 4, 1199 (2018).","journal-title":"JAMA Oncol."},{"key":"786_CR32","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1200\/JCO.2018.36.15_suppl.506","volume":"36","author":"HM Earl","year":"2018","unstructured":"Earl, H. M., Hiller, L., Vallier, A.-L., Loi, S., Howe, D., Higgins, H. B. et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. J. Clin. Oncol. 36, 506\u2013506 (2018).","journal-title":"J. Clin. Oncol."},{"key":"786_CR33","doi-asserted-by":"publisher","unstructured":"Pond\u00e9, N., Gelber, R. D., Piccart, M. PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? npj Breast Cancer. https:\/\/doi.org\/10.1038\/s41523-018-0098-y (2019).","DOI":"10.1038\/s41523-018-0098-y"},{"key":"786_CR34","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano, J. L., Lancellotti, P., Rodriguez Mu\u00f1oz, D., Aboyans, V., Asteggiano, R., Galderisi, M. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J. 37, 2768\u20132801 (2016).","journal-title":"Eur. Heart J."},{"key":"786_CR35","doi-asserted-by":"publisher","unstructured":"Eiger, D., Pond\u00e9, N. F., Azambuja, E. de. Pertuzumab in HER2-positive early breast cancer: current use and perspectives. Future Oncol. https:\/\/doi.org\/10.2217\/fon-2018-0896 (2019).","DOI":"10.2217\/fon-2018-0896"},{"key":"786_CR36","doi-asserted-by":"publisher","unstructured":"Mohan, N., Shen, Y., Endo, Y., ElZarrad, M. K., Wu, WJ. Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol. Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.mct-15-0741 (2016).","DOI":"10.1158\/1535-7163.mct-15-0741"},{"key":"786_CR37","doi-asserted-by":"publisher","unstructured":"O\u2019Connor, T., Soto-Perez-de-Celis, E., Blanchard, S., Chapman, A., Kimmick, G., Muss, H. et al. Abstract P5-21-08: tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer. Am. Assoc. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS17-P5-21-08 (2018).","DOI":"10.1158\/1538-7445.SABCS17-P5-21-08"},{"key":"786_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10549-013-2710-z","volume":"142","author":"D Miles","year":"2013","unstructured":"Miles, D., Baselga, J., Amadori, D., Sunpaweravong, P., Semiglazov, V., Knott, A. et al. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res. Treat. 142, 89\u201399 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"786_CR39","doi-asserted-by":"publisher","unstructured":"Nowsheen, S., Aziz, K., Park, J. Y., Lerman, A., Villarraga, H. R., Ruddy, K. J. et al. Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction. J. Am. Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.118.008637 (2018).","DOI":"10.1161\/JAHA.118.008637"},{"key":"786_CR40","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2018.36.15_suppl.1038","volume":"36","author":"F Lynce","year":"2018","unstructured":"Lynce, F., Barac, A., Geng, X., Dang, C. T., Yu, A. F., Smith, K. L. et al. SAFE-HEaRt: a pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function. J. Clin. Oncol. 36, 1038\u20131038, (2018).","journal-title":"J. Clin. Oncol."},{"key":"786_CR41","doi-asserted-by":"publisher","unstructured":"Ewer, M. S., Herson, J. False positive cardiotoxicity events in cancer-related clinical trials: risks related to imperfect noninvasive parameters. Chemotherapy. https:\/\/doi.org\/10.1159\/000495147 (2019).","DOI":"10.1159\/000495147"},{"key":"786_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/EDE.0000000000000437","volume":"27","author":"JH Lubin","year":"2016","unstructured":"Lubin, J. H., Couper, D., Lutsey, P. L., Woodward, M., Yatsuya, H. & Huxley, R. R. Risk of cardiovascular disease from cumulative cigarette use and the impact of smoking intensity. Epidemiology 27, 395\u2013404 (2016).","journal-title":"Epidemiology"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0786-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0786-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0786-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:07:48Z","timestamp":1684616868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0786-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5,12]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0786-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"13 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board at each participating centre approved the ALTTO trial protocol. All patients provided written informed consent, as previously reported.<sup>5<\/sup>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that all data supporting the findings of this study are available within the article and its Supplementary Information files or are available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"D.E.: funding for his ESMO fellowship (2018\u20132019) provided by Novartis; research grant for his institute: Roche\/GNE, Radius, Astra-Zeneca, Lilly, MSD, Novartis, Synthon, Servier, and Pfizer; N.F.P.: honoraria: MundiPharma, Astrazeneca; travel grants: Novartis, Astrazeneca, MundiPharma, Roche; D.A.T.: none; A.M.A.: none; M.P.: Board Member (Scientific Board): Oncolytics, Radius; Consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Oncolytics, Periphagen, Pfizer, Roche, Seattle Genetics; Research grants to her Institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon; Speakers bureau\/stock ownership: none; F.H.: research grant for her Institute (for the conduct of the ALTTO trial): GSK, Novartis; O.W.: employee of Novartis Pharma AG; S.C.: Research grant from Merck & Co. and Array BioPharma. Consultation\/Advisory Board from Novartis, Syndax Pharmaceuticals Inc., Puma Biotechnology, and Immunomedics Incs.; A.D.: Research funding from GSK during the study; J.R.K.: none; H.G.: received honoraria as speaker from AstraZeneca, Roche, BMS, and Novartis; I.L.: none; R.J.R.: none; M.S.E.: ownership or stock\/financial holdings: none; Book royalties: Elsevier and Peoples Medical Publishing House; Consulting agreements with Boehringer-Ingelheim, Bayer, Merck, and Daiichi Sankyo; T.S.: none; E.A.: honoraria and advisory board: Roche\/GNE; travel grants: Roche\/GNE, GSK\/Novartis; co-principal investigator of the LORELEI trial (NCT02273973); research grant for his institute: Roche\/GNE, Radius, Astra-Zeneca, Lilly, MSD, Novartis, Synthon, Servier, and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Novartis has funded all the statistical analysis for ALTTO Cardiac. The ALTTO trial was supported by GlaxoSmithKline (GSK) and the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology, CA025224 to the legacy North Central Cancer Treatment Group (NCCTG), and CA077202 to the National Cancer Information Center (NCIC) Clinical Trials group. NCIC CTG participation was also supported by the Canadian Cancer Society Research Institute under Award Number 015469 and 021039.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}